Cargando…

Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of “Second Hit” in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma

BACKGROUND AND OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is characterized by the occurrence of pathogenic variants in BRCA1/2 in 5–6% of patients. Biallelic loss of BRCA1/2 enriches for response to platinum agents and poly (ADP-ribose) polymerase 1 inhibitors. There is a dearth of evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng-Lin, Binbin, Rainone, Michael, Varghese, Anna M., Yu, Kenneth H., Park, Wungki, Berger, Michael, Mehine, Miika, Chou, Joanne, Capanu, Marinela, Mandelker, Diana, Stadler, Zsofia K., Birsoy, Ozge, Jairam, Sowmya, Yang, Ciyu, Li, Yirong, Wong, Donna, Benhamida, Jamal K, Ladanyi, Marc, Zhang, Liying, O’Reilly, Eileen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626413/
https://www.ncbi.nlm.nih.gov/pubmed/36178671
http://dx.doi.org/10.1007/s40291-022-00614-1
_version_ 1784822725372542976
author Zheng-Lin, Binbin
Rainone, Michael
Varghese, Anna M.
Yu, Kenneth H.
Park, Wungki
Berger, Michael
Mehine, Miika
Chou, Joanne
Capanu, Marinela
Mandelker, Diana
Stadler, Zsofia K.
Birsoy, Ozge
Jairam, Sowmya
Yang, Ciyu
Li, Yirong
Wong, Donna
Benhamida, Jamal K
Ladanyi, Marc
Zhang, Liying
O’Reilly, Eileen M.
author_facet Zheng-Lin, Binbin
Rainone, Michael
Varghese, Anna M.
Yu, Kenneth H.
Park, Wungki
Berger, Michael
Mehine, Miika
Chou, Joanne
Capanu, Marinela
Mandelker, Diana
Stadler, Zsofia K.
Birsoy, Ozge
Jairam, Sowmya
Yang, Ciyu
Li, Yirong
Wong, Donna
Benhamida, Jamal K
Ladanyi, Marc
Zhang, Liying
O’Reilly, Eileen M.
author_sort Zheng-Lin, Binbin
collection PubMed
description BACKGROUND AND OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is characterized by the occurrence of pathogenic variants in BRCA1/2 in 5–6% of patients. Biallelic loss of BRCA1/2 enriches for response to platinum agents and poly (ADP-ribose) polymerase 1 inhibitors. There is a dearth of evidence on the mechanism of inactivation of the wild-type BRCA1 allele in PDAC tumors with a germline BRCA1 (gBRCA1) pathogenic or likely pathogenic variant (P/LPV). Herein, we examine promotor hypermethylation as a “second hit” mechanism in patients with gBRCA1-PDAC. METHODS: We evaluated patients with PDAC who underwent Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) somatic and germline testing from an institutional database. DNA isolated from tumor tissue and matched normal peripheral blood were sequenced by MSK-IMPACT. In patients with gBRCA1-PDAC, we examined the somatic BRCA1 mutation status and promotor methylation status of the tumor BRCA1 allele via a methylation array analysis. In patients with sufficient remaining DNA, a second methylation analysis by pyrosequencing was performed. RESULTS: Of 1012 patients with PDAC, 19 (1.9%) were identified to harbor a gBRCA1 P/LPV. Fifteen patients underwent a methylation array and the mean percentage of BRCA1 promotor methylation was 3.62%. In seven patients in whom sufficient DNA was available, subsequent pyrosequencing confirmed an unmethylated BRCA1 promotor. Loss of heterozygosity was detected in 12 of 19 (63%, 95% confidence interval 38–84) patients, demonstrating loss of heterozygosity is the major molecular mechanism of BRCA1 inactivation in PDAC. Two (10.5%) cases had a somatic BRCA1 mutation. CONCLUSIONS: In patients with gBRCA1-P/LPV-PDAC, loss of heterozygosity is the main inactivating mechanism of the wild-type BRCA1 allele in the tumor, and methylation of the BRCA1 promoter is a distinctly uncommon occurrence.
format Online
Article
Text
id pubmed-9626413
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-96264132022-11-03 Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of “Second Hit” in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma Zheng-Lin, Binbin Rainone, Michael Varghese, Anna M. Yu, Kenneth H. Park, Wungki Berger, Michael Mehine, Miika Chou, Joanne Capanu, Marinela Mandelker, Diana Stadler, Zsofia K. Birsoy, Ozge Jairam, Sowmya Yang, Ciyu Li, Yirong Wong, Donna Benhamida, Jamal K Ladanyi, Marc Zhang, Liying O’Reilly, Eileen M. Mol Diagn Ther Original Research Article BACKGROUND AND OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is characterized by the occurrence of pathogenic variants in BRCA1/2 in 5–6% of patients. Biallelic loss of BRCA1/2 enriches for response to platinum agents and poly (ADP-ribose) polymerase 1 inhibitors. There is a dearth of evidence on the mechanism of inactivation of the wild-type BRCA1 allele in PDAC tumors with a germline BRCA1 (gBRCA1) pathogenic or likely pathogenic variant (P/LPV). Herein, we examine promotor hypermethylation as a “second hit” mechanism in patients with gBRCA1-PDAC. METHODS: We evaluated patients with PDAC who underwent Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) somatic and germline testing from an institutional database. DNA isolated from tumor tissue and matched normal peripheral blood were sequenced by MSK-IMPACT. In patients with gBRCA1-PDAC, we examined the somatic BRCA1 mutation status and promotor methylation status of the tumor BRCA1 allele via a methylation array analysis. In patients with sufficient remaining DNA, a second methylation analysis by pyrosequencing was performed. RESULTS: Of 1012 patients with PDAC, 19 (1.9%) were identified to harbor a gBRCA1 P/LPV. Fifteen patients underwent a methylation array and the mean percentage of BRCA1 promotor methylation was 3.62%. In seven patients in whom sufficient DNA was available, subsequent pyrosequencing confirmed an unmethylated BRCA1 promotor. Loss of heterozygosity was detected in 12 of 19 (63%, 95% confidence interval 38–84) patients, demonstrating loss of heterozygosity is the major molecular mechanism of BRCA1 inactivation in PDAC. Two (10.5%) cases had a somatic BRCA1 mutation. CONCLUSIONS: In patients with gBRCA1-P/LPV-PDAC, loss of heterozygosity is the main inactivating mechanism of the wild-type BRCA1 allele in the tumor, and methylation of the BRCA1 promoter is a distinctly uncommon occurrence. Springer International Publishing 2022-09-30 2022 /pmc/articles/PMC9626413/ /pubmed/36178671 http://dx.doi.org/10.1007/s40291-022-00614-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Zheng-Lin, Binbin
Rainone, Michael
Varghese, Anna M.
Yu, Kenneth H.
Park, Wungki
Berger, Michael
Mehine, Miika
Chou, Joanne
Capanu, Marinela
Mandelker, Diana
Stadler, Zsofia K.
Birsoy, Ozge
Jairam, Sowmya
Yang, Ciyu
Li, Yirong
Wong, Donna
Benhamida, Jamal K
Ladanyi, Marc
Zhang, Liying
O’Reilly, Eileen M.
Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of “Second Hit” in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma
title Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of “Second Hit” in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma
title_full Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of “Second Hit” in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma
title_fullStr Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of “Second Hit” in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma
title_full_unstemmed Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of “Second Hit” in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma
title_short Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of “Second Hit” in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma
title_sort methylation analyses reveal promoter hypermethylation as a rare cause of “second hit” in germline brca1-associated pancreatic ductal adenocarcinoma
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626413/
https://www.ncbi.nlm.nih.gov/pubmed/36178671
http://dx.doi.org/10.1007/s40291-022-00614-1
work_keys_str_mv AT zhenglinbinbin methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT rainonemichael methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT vargheseannam methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT yukennethh methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT parkwungki methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT bergermichael methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT mehinemiika methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT choujoanne methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT capanumarinela methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT mandelkerdiana methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT stadlerzsofiak methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT birsoyozge methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT jairamsowmya methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT yangciyu methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT liyirong methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT wongdonna methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT benhamidajamalk methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT ladanyimarc methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT zhangliying methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma
AT oreillyeileenm methylationanalysesrevealpromoterhypermethylationasararecauseofsecondhitingermlinebrca1associatedpancreaticductaladenocarcinoma